Label Changes for:

Isentress (raltegravir potassium) 400 mg tablets

January 2009

Changes have been made to the ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- January 2009

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.


Summary View

ADVERSE REACTIONS

  • Postmarketing Experience
    • depression
    • suicidal ideation and behaviors

PATIENT PACKAGE INSERT

  • What are the possible side effects of...
Hide
(web3)